Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival

Table 5 Clinical characteristics of patients with non-small cell lung carcinoma and malignant melanoma who developed gastrointestinal-immune-related adverse event

Characteristic	NSCLC, n = 12	MM, n = 13
Age, yr	67 ± 11	67 ± 12
Sex, n
Male	10	9
Female	2	4
BMI, kg/m2	22.2 ± 3.7	22.1 ± 4.4
ECOG PS, n
0-1	12	13
2-3	0	0
Stage, n
III	1	2
IV	11	11
Latest ICI, n
Nivolumab	2	5
Pembrolizumab	8	3
Atezolizumab	2	0
Ipilimumab	0	5
Nivolumab + ipilimumab	0	0
Diarrhea frequency	4.3 ± 1.8	5.5 ± 2.5
CTCAE Grade, n
1	4	3
2	7	8
3	1	2
Median ICI duration before GI-irAE onset (d), median (range)	60 (7-567)	75 (24-733)
Treatment with ICIs after the onset of GI-irAEs
Continued or resumed	8	10
Discontinued	4	3

BMI: Body mass index; CTCAE: Common Terminology Criteria for Adverse Events; ECOG PS: Eastern Cooperative Oncology Group performance status; GI-irAE: Gastrointestinal-immune-related adverse event; ICI: Immune checkpoint inhibitor; MM: Malignant melanoma; NSCLC: Non-small cell lung carcinoma.